Submission Details
| 510(k) Number | K231137 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | April 21, 2023 |
| Decision Date | May 19, 2023 |
| Days to Decision | 28 days |
| Submission Type | Traditional |
| Review Panel | Toxicology (TX) |
| Summary | Summary PDF |
K231137 is an FDA 510(k) clearance for the Xenta Drug Screen Cup, Xenta Drug Screen Dipcard, a Enzyme Immunoassay, Amphetamine (Class II — Special Controls, product code DKZ), submitted by Xenta Biomedical Science Co., Ltd. (Guangzhou, CN). The FDA issued a Cleared decision on May 19, 2023, 28 days after receiving the submission on April 21, 2023. This device falls under the Toxicology review panel. Regulated under 21 CFR 862.3100.
| 510(k) Number | K231137 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | April 21, 2023 |
| Decision Date | May 19, 2023 |
| Days to Decision | 28 days |
| Submission Type | Traditional |
| Review Panel | Toxicology (TX) |
| Summary | Summary PDF |
| Product Code | DKZ — Enzyme Immunoassay, Amphetamine |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 862.3100 |